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Abstract
Background: The molecular mechanisms of CC (cholangiocarcinoma) oncogenesis and progression are poorly
understood. This study aimed to determine the genome-wide expression of genes related to CC oncogenesis and
sarcomatous transdifferentiation.
Methods: Genes that were differentially expressed between CC cell lines or tissues and cultured normal biliary
epithelial (NBE) cells were identified using DNA microarray technology. Expressions were validated in human CC
tissues and cells.
Results: Using unsupervised hierarchical clustering analysis of the cell line and tissue samples, we identified a set
of 342 commonly regulated (>2-fold change) genes. Of these, 53, including tumor-related genes, were
upregulated, and 289, including tumor suppressor genes, were downregulated (<0.5 fold change). Expression of
SPP1, EFNB2, E2F2, IRX3, PTTG1, PPARg, KRT17, UCHL1, IGFBP7 and SPARC proteins was immunohistochemically
verified in human and hamster CC tissues. Additional unsupervised hierarchical clustering analysis of sarcomatoid
CC cells compared to three adenocarcinomatous CC cell lines revealed 292 differentially upregulated genes (>4-
fold change), and 267 differentially downregulated genes (<0.25 fold change). The expression of 12 proteins was
validated in the CC cell lines by immunoblot analysis and immunohistochemical staining. Of the proteins analyzed,
we found upregulation of the expression of the epithelial-mesenchymal transition (EMT)-related proteins VIM and
TWIST1, and restoration of the methylation-silenced proteins LDHB, BNIP3, UCHL1, and NPTX2 during sarcomatoid
transdifferentiation of CC.
Conclusion: The deregulation of oncogenes, tumor suppressor genes, and methylation-related genes may be
useful in identifying molecular targets for CC diagnosis and prognosis.
Background
Cholangiocarcinoma (CC) is a highly lethal adenocarci-
noma arising from bile duct epithelial cells. CC accounts
for approximately 15% of the total liver cancer cases
worldwide, and its incidence is rising [1,2]. The prog-
nosis for CC is quite poor because of difficulties in early
diagnosis, and relative resistance of the tumors to che-
motherapy [3,4]. At the time of diagnosis, approximately
70% of CC patients have an occult metastasis or
advanced local disease that precludes curative resection.
Of candidates for curative resection, 30% develop recur-
rent disease at the anastomotic site or within the intra-
hepatic biliary tree, and succumb to disease progression
or cholangitis [5]. Established risk factors for ductal cho-
langiocarcinomas include primary sclerosing cholangitis,
infection with Clonorchis sinensis or Opisthorchis viver-
rini (liver flukes), Calori’s disease, congenital choledo-
chal cysts, and chronic intrahepatic lithiasis [6].
However, for most CCs, the cause is unknown.
Recently, molecular investigations have provided evi-
dence that CC carcinogenesis involves a number of
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any medium, provided the original work is properly cited.genetic alterations, including activating point mutations
in the K-ras oncogene, and in p53 and BRAF [7-9]. The
deregulated expression of an u m b e ro fo t h e rg e n e sh a s
also been reported, and cyclooxygenase-2 and c-erbB-2
are frequently overexpressed in CCs, suggesting an
involvement in early biliary carcinogenesis [10]. In addi-
tion, increased expression of interleukin-6 is frequently
observed in CC [11]. CC also develops after the liver-
specific targeted disruption of the tumor suppressors
SMAD4 and PTEN [12]. The incidence of sarcomatoid
changes in CC is estimated to be approximately 5% [13],
and sarcomatoid cells are thought to result from de-dif-
ferentiation of ordinary carcinomatous CC cells. Sarco-
matoid neoplasms are highly aggressive and have a
poorer survival rate than ordinary CCs [14], but the
underlying molecular alterations, which may be related
to the epithelial-mesenchymal transition (EMT), remain
unclear. Little extensive genome-wide information about
altered gene expression in CCs is available, and only a
few published studies have reported a comprehensive
analysis of gene expression among biliary tract cancers
in general [15,16]. The advancement of microarray tech-
nology now enables us to analyze genome-wide gene
expression in a single experiment, opening avenues for
the molecular classification of tumors, detection of the
biological nature of tumors, and prediction of prognosis
and sensitivity to treatments.
In this study, we generated genome-wide gene expres-
sion profiles of 10 cell lines (9 CC cell lines and 1
immortalized cholangiocyte line), and 19 CC tissues
using a BeadChip oligonucleotide technology containing
48,000 genes. This procedure allowed us to observe a
comprehensive pattern of gene expression in CC com-
pared to cultured normal biliary epithelia (NBE). In
addition, we identified a set of genes associated with sar-
comatoid transdifferentiation. These data are useful not
only because they provide a more profound understand-
ing of cholangiocarcinogenesis and transdifferentiation,
but also because they may help to develop diagnostic
tools and improve the accuracy of CC prognosis.
Methods
Cell lines and cultures
Tumor tissues were obtained from surgical specimens
and biopsy specimens in Korean cholangiocarcinoma
patients. Tumor tissues were washed three times in
Opti-MEM I (Gibco, Grand Island, NY) containing anti-
biotics. Washed tissue was transferred to a sterile Petri
dish and finely minced with scalpels into 1- to 2-mm
3
fragments. Tissue fragments in culture medium were
seeded in T25 culture flasks (Corning, Medfield, MA) in
Opti-MEM supplemented with 10% fetal bovine serum
(FBS, Gibco), 30-mM sodium bicarbonate and antibio-
tics. Tumor cells were cultured undisturbed and
passaged as described [17]. Near the 20th passage, the
medium was changed from Opti-MEM I to DMEM sup-
plemented with 10% FBS and antibiotics. NBE cells were
isolated from mucosal slices of normal bile ducts, with
informed consent from liver transplantation donors, and
ex-vivo cultured in T25 culture flasks in Opti-MEM sup-
plemented with 10% FBS, 30 mM sodium bicarbonate
and antibiotics at 37°C with 5% CO2 in air. Near-conflu-
ent NBE cells were harvested and stored at -80°C until
use. Cells were routinely tested for mycoplasma and
found to be negative using a Gen Probe kit (San Diego,
CA). CC cell lines are in Table 1.
5-Aza-2’-deoxycytidine (Aza) treatment
Choi-CK, Cho-CK, and JCK cells were seeded at 1 × 10
6
cells/ml. After overnight culture, cells were treated with
5 μM of the DNA methylating agent Aza (Sigma-
Aldrich, St. Louis, MO) for 4 days, and then harvested.
Patients and tissue samples
CC tissues were obtained with informed consent from
Korean patients who underwent hepatectomy and com-
mon bile duct exploration at Chonbuk National University
Hospital. All tumors were clinically and histologically diag-
nosed as cholangiocarcinoma. Detailed clinocopathological
data of the 19 samples are in Table 2. All samples were
immediately frozen in nitrogen tanks. Patient informa-
tion was obtained from medical records. Clinical stage
was determined according to the International Hepato-
Pancreato-Biliary Association (IHPBA) classification [18].
Primer labeling and Illumina Beadchip array hybridization
Total RNA from CC samples was isolated using TRIzol
reagent (Invitrogen, CA) according to the manufacturer’s
instructions. RNA quality was determined by gel electro-
phoresis, and concentrations were determined using an
Ultrospec 3100 pro spectrophotometer (Amersham
Bioscience, Buckinghamshire, UK). Biotin-labeled cRNA
samples for hybridization were prepared according to
Illumina’s recommended sample-labeling procedure:
500 ng of total RNA was used for cDNA synthesis, fol-
lowed by an amplification/labeling step (in vitro tran-
scription) to synthesize biotin-labeled cRNA using the
Illumina TotalPrep RNA Amplification kit (Ambion Inc.,
Austin, TX). cRNA concentrations were measured by the
RiboGreen method (Quant-iT RiboGreen RNA assay kit;
Invitrogen-Molecular Probes, ON, Canada) using a Vic-
tor3 spectrophotometer (PerkinElmer, CT), and cRNA
quality was determined on a 1% agarose gel. Labeled,
amplified material (1500 ng per array) was hybridized to
Illumina Human-6 BeadChips v2 containing 48,701
probes for 24,498 genes, according to the manufacturer’s
instructions (Illumina, San Diego, CA). Array signals were
developed by Amersham fluorolink streptavidin-Cy3 (GE
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Page 2 of 15Healthcare Bio-Sciences, Little Chalfont, UK) following the
BeadChip manual. Arrays were scanned with an Illumina
Bead-array Reader confocal scanner (BeadStation
500GXDW; Illumina) according to the manufacturer’s
instructions. Array data processing and analysis were per-
formed using Illumina BeadStudio software. The BeadStu-
dio Gene Expression Module is a tool for analyzing gene
expression data from scanned microarray images gener-
ated by the Illumina BeadArray Reader.
Data analysis
Normalization algorithms were used to adjust sample sig-
nals to minimize the effects of variation from non-
biological factors. To reduce variation between microar-
rays, the intensity values for samples in each microarray
were rescaled using a quartile normalization method in
the BeadStudio module. Measured gene expression values
were log2-transformed and median-centered across genes
and samples for further analysis. To generate an overview
of the gene expression profile and to identify major rela-
tionships in cell lines, we used unsupervised hierarchical
clustering analysis. Genes with an expression ratio of at
least a two-fold difference relative to the median gene
expression level across all samples in at least 10% of sam-
ples were selected for clustering analysis. Average linkage
hierarchical cluster analysis was carried out using a
Table 1 Clinicopathological features of nine patients with intrahepatic cholangiocarcinomas used to generate
CC cells lines
Patient No Cell line Age/Sex T/N/M Stage CA19-9 (U/ml) Differentiation Tumori genicity Comments
1 CK-Choi (Choi-CK) M/68 IVB 184 WD +
2 CK-Cho (Cho-CK) M/82 IVA 500 MD +
3 CK-J (JCK) M/72 IVA 125 PD + C. sinensis
4 CK-S (SCK) M/68 IVA 235.6 PD + Sarcomatoid
5 CK-L1 M/46 IVA 0.01 PD + Combined with HCC
6 CK-L2 M/65 III 2050.1 MD +
7 CK-P1 M/66 IVA 23.7 MD -
8 CK-P2 F/66 IVA 121.4 MD +
9 CK-Y1 M/52 IVA 0.01 PD + Combined with HCC
M, male; F, female; C. sinensis, clonorchis sinensis; HCC, hepatocellular carcinoma; WD, well differentiated; MD, moderately differentiated; PD, poorly
differentiated.
*International Hepato-Pancreato-Biliary Association classification.
Table 2 Clinicopathological features of 19 CC samples used for microarray analysis
Sample No Age/Sex Loca tion Size (cm) T N M Stage Gross appearance Differentiation Sub-class Comment
1 (CC-GHS) 68/F L 8.7 × 5.4 3 1 0 IVA MF PD A
2 (CC-CYS) 57/M L NA 3 1 0 IVA MF +PDI MD A
3 (CC-LJS) 42/M A NA 1 0 0 I ID WD B Intraductal papillary
4 (CC-BJP) 62/M P 7.8 × 5.6 1 0 0 I ID WD B Intraductal papillary
5 (CC-HSR) 66/M AP 7.3 × 6 2 0 0 II MF MD B
6 (CC-HSW) 59/M AP 9 × 6.8 2 0 0 II MF MD B
7 (CC-CSB) 60/M L 4 × 4.5 3 0 0 III MF MD B
8 (CC-SJS) 71/M A 2.1 × 1.9 1 0 0 II MF WD B
9 (CC-HDS) 63/M CBD 1.1 × 0.9 1 1 1 IVB ID MD B
10 (CC-KHC) 47/M L 14 × 10 4 0 0 IVA MF PD C
11 (CC-LHG) 42/M L 5.6 × 3.9 3 1 0 IVA MF PD C Combined with HCC
12 (CC-LSH) 40/F P 8.6 × 4 2 0 1 IVB MF PD C Combined with HCC
13 (CC-KHS) 70/F L 8.5 × 4.8 3 0 1 IVB MF +PDI PD C Combined with HCC
14 (CC-LMS) 38/F AP 5 × 3.7 4 0 1 IVB MF PD C Combined with HCC
15 (CC-KJA) 39/F LP 6 × 5 4 0 0 IVA MF MD C Combined with HCC
16 (CC-JSJ) 64/M L 0.5 × 0.5 2 0 1 IVB ID PD C
17 (CC-YCU) 53/M L 4.3 × 2.1 3 1 0 IVA MF MD C
18 (CC-GMG) 50/M L 7 × 3.5 2 0 0 II MF MD C
19 (CC-BSD) 67/M L 2.9 × 2.7 4 0 0 IVA MF+P야 PD C
HCC, hepatocellular carcinoma; M, male; F, female; A, anterior segment; P, posterior segment; Med, medial segment; L, lateral segment; MF, mass forming type;
PDI, periductal infiltrating type; IDG, intraductal growth type; WD, well differentiated; MD, moderately differentiated; PD, poorly differentiated; NA, not available.
*International Hepato-Pancreato-Biliary Association classification.
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GeneCluster/TreeView program (http://rana.lbl.gov/Eisen-
Software.htm). Expression profiles for the differentially
expressed genes were selected by t-test with false discovery
rate (FDR) and q-values as gene significance measures,
using R software (version 2.5). Because of varying signifi-
cance in the analyzed comparisons, using a fixed FDR (or
q-value) cut-off value was not practical. Therefore, we
used t-test P = 0.01. To ascertain biological relevance, a
fold-change cut-off value of 2 or 4 from the mean was
chosen. The gene ontology (GO) program (http://david.
abcc.ncifcrf.gov/) was used to categorize genes in sub-
groups based on biological function. Values for each GO
group were calculated as a percentage of total mRNA
change. For example, the Fisher exact test was used to
determine whether the proportions of genes in each cate-
gory differed by group. The microarray data were regis-
tered with the Gene Expression Omnibus (GEO) database
(Accession No. GSE22633)
Immunoblotting
Extracted protein (30 μg) from cell lysates was resolved
by SDS-PAGE and transferred to a nitrocellulose mem-
brane. Membranes were incubated for 1 h at room tem-
perature with primary antibody at 1:1000 dilution. After
incubation, blots were washed three times in TBS/0.1%
Tween 20. Immunoreactivity was detected using alkaline
phosphatase-conjugated goat anti-rabbit IgG or a com-
mercial chemiluminescence detection kit (Amersham),
according to the manufacturer’s instructions.
Immunohistochemistry
Immunohistochemical staining was performed on for-
malin-fixed, paraffin-embedded 4-μM tissue sections, as
described preciously [19]. Briefly, a deparaffinized sec-
tion was pretreated by microwave epitope retrieval (750
W during 15 min in citrate buffer 10 mmol; pH 6.0)
after rehydration. Before applying primary antibodies,
the endogenous peroxidase activity was inhibited with
3% hydrogen peroxide, and a blocking step with biotin
and bovine albumin was performed. Primary monoclo-
nal or polyclonal antibodies were detected using a
secondary biotinylated antibody and a streptavidin-
horseradish peroxidase conjugate according to the man-
ufacturer’s instructions (DAKO, Glostrup, Denmark).
Counterstaining was performed using Meyer’s hematox-
ylin. Tumors were evaluated for the percentage of posi-
tive cells and the staining intensity. Negative controls
were samples incubated with either PBS or mouse IgG1
instead of primary antibody.
Real-time RT-PCR
RNA prepared from dissected tissues was precipitated
with isopropanol and dissolved in DEPC-treated
distilled water. Reverse transcription (RT) was per-
formed using 2 μgt o t a lR N A ,5 0μM decamer and
1 μl (200 units) and RT-PCR Superscript II (Invitro-
gen) at 37°C for 50 min, as previously described. Speci-
fic primers for each gene were designed using the
Primerdepot website (http://primerdepot.nci.nih.gov/)
and are in Additional file 1. The control 18S ribosomal
RNA primer was from Applied Biosystems (Foster
City, CA) and was used as the invariant control. The
real-time RT-PCR reaction mixture consisted of 10 ng
reverse-transcribed total RNA, 167 nM forward and
reverse primers, and 2 × PCR master mixture in a final
volume of 10 μl PCR, was in 384-well plates using
the ABI Prism 7900HT Sequence Detection System
(Applied Biosystems).
Animal model of cholangiocarcinoma
The hamster CC model was modified from a previous
study [20]. On the first day of the experiment, hamsters
in the experimental group were infected with 15 meta-
cercariae of the liver fluke, C. sinensis.O n ed a ya f t e r
parasite infestation, hamsters received 15 ppm of
dimethylnitrosamine (DMN; Kasei, Japan) in the drink-
ing water for 4 weeks with a normal diet. Thereafter,
hamsters were given tap water with a normal diet for
the rest of the study. An interim stage of cholangiocarci-
nogenesis was confirmed at 8 weeks after experiment
initiation. Control and CC model hamsters were main-
tained for a total of 27 weeks for CC to develop.
Results
Gene expression patterns distinguish CC cells from
cultured NBE cells
Using BeadChip microarray analysis, we compared the
gene expression profiles of nine CC cell lines, an
immortalized biliary epithelial cell line, and four types of
NBE cells. We selected 828 unique genes with a 2-fold
or greater expression difference from the mean, with a
P <0 . 0 1b yt-test. Unsupervised hierarchical clustering
analysis of all samples was based on the similarity in the
expression pattern of all genes (Figure 1). Cell samples
were separated into two main groups, the NBE cluster,
and the transformed and immortalized biliary epithelial
cells (CCC cluster). Each distinctive gene cluster was
identified by delineation using a hierarchical clustering
dendrogram. Cluster I consisted of genes upregulated in
CC cells, which included tumor-related genes such as
LGR4, AGR2, PCAF, TMEM97, FRAT2, EFNB2 and
ZIC2 [21-27]. Cluster II included genes underexpressed
in CC cells. These were mainly tumor suppressor genes
such as GREM1, THY1, STC2, SERPINE1, SPARC and
TAGLN [28-33]. Cluster III wasg e n e su p r e g u l a t e di n
NBE cells, and contained the PDGFRA, CD248,a n d
BDKRB1 genes.
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Figure 1 Unsupervised hierarchical clustering of four biliary epithelial cells, one immortalized cholangiocyte cell line and nine CC cells.
Unsupervised hierarchical clustering separated the samples into two main groups, normal biliary epithelial cells (NBE) isolated from mucosal
slices of normal bile ducts and ex-vivo cultured as described in Methods, and cholangiocarcinoma cells (CCC). Data are in matrix format, with
columns representing individual cell lines and rows representing each gene. Red, high expression; green, low expression; black, no significant
change in expression level between the mean and sample. A hierarchical clustering algorithm was applied to all cells and genes using the 1 -
Pearson correlation coefficient as a similarity measure. Raw data for a single array were summarized using Illumina BeadStudio v3.0 and output
to the user was as a set of 43,148 values for each individual hybridization. We selected 828 unique genes with a two-fold or greater difference
from the mean and P < 0.01 by t-test, for hierarchical clustering analysis. Specific gene clusters (Cluster 1 through Cluster III) were identified in
the hierarchical cluster of the genes differentially expressed in CCC compared with NBE. CC, cholangiocarcinoma; IMC, immortalized
cholangiocytes.
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cultured NBE cells
Using BeadChip microarrays, gene expression profiles of
19 CC tissues and 4 types of NBE cells were compared.
We selected 1798 unique genes with a 2-fold or greater
differences from the mean difference with a P <0 . 0 1b y
t-test. Unsupervised hierarchical clustering analysis was as
described above (Figure 2A). All samples separated into
two main groups, NBE and CC tissues (CCT). Each dis-
tinctive gene cluster was identified using a hierarchical
clustering dendrogram as above. Intriguingly, the CC sam-
ple cluster was divided into two subclasses by tumor dif-
ferentiation: differentiated (Df) and undifferentiated (Udf).
Clustering data for the CC group revealed three clusters.
C l u s t e rIh a dg e n e su p r e g u l a t e di nN B Ea n dd o w n r e g u -
lated in CCT including SERPINB2, PAPPA, LRRC17, and
GREM1. Cluster II contained genes upregulated in the Df
CCT and downregulated in NBE. Cluster III included
genes upregulated in poorly differentiated or Udf CCT,
and downregulated in NBE. A supervised hierarchical clus-
tering analysis was performed between the NBE class, and
the Df and the Udf subclasses based on the similarity of
expression pattern of all genes (Figure 2B and 2C). We
selected 420 differentially expressed genes in the Df sub-
class, and 646 genes in the Udf subclass for comparison
with the NBE class (Additional files 2 and 3).
Differential expression and verification of CC-related
genes
We compared the gene lists from the cell-based and tis-
sue-based databases, and selected 342 commonly regu-
lated genes, including 53 commonly upregulated genes
and 289 commonly downregulated genes (Figure 3A).
The top 25 commonly regulated genes in both CCC and
CCT compared to NBE are in Additional file 4. To ver-
ify the microarray data, we examined the mRNA levels
of the identified genes using real-time RT-PCR in
human CC tissues. We selected five up-regulated genes
from the commonly upregulated genes of both the cell
and tissue sample classes (Figure 3B). We also chose the
IRX3, PTTG1,a n dPPARg genes, which were highly
upregulated in only the cell sample class. These genes
were preferentially expressed in CC cells and tissues.
We also examined the expression of the commonly
downregulated KRT17 and UCHL1 genes, as well as the
cellular downregulated IGFBP7 and SPARC genes using
real-time RT-PCR in human CC. The human NBE
showed substantial expression of CK-17, UCHL1,
IGFBP7 and SPARC, which were barely detected in CC
tissues (Figure 3C).
Immunohistochemical analysis of CC-related genes
To confirm the reliability of the microarray data and the
robustness of the strategy for identifying genes with
altered expression, we examined the protein levels of
the identified genes using immunohistochemical analysis
of human tissues (Figure 4A). We selected three upregu-
lated genes from the genes that were upregulated in
both cell and tissue samples. The SPP1, EFNB2 and
E2F2 proteins were abnormally overexpressed in the CC
cell cytoplasm, and weakly or barely expressed in HCC.
We also examined the IRX3, PTTG1, and PPARg pro-
teins, which were highly upregulated in only the cell
samples. IRX3 was the most highly upregulated, and we
was strongly expressed in the nucleus of CC cells in the
tissue sections, but was barely detectable in the NBE
nuclei. PTTG1 and PPARg were abnormally overex-
pressed in the CC cell cytoplasm, and their expression
was attenuated in poorly differentiated CC. Next, we
also used immunohistochemical staining of human CC
to examine the KRT17 and UCHL1 proteins, whose
genes were both downregulated in CC cells and tissues,
and the IGFBP7 and SPARC proteins, which were
downregulated in CC cells only. Human NBE showed
substantial expression of the CK-17, UCHL1, IGFBP7,
and SPARC proteins, but these were barely detectable in
CC tissue. However, KRT-17 was clearly positive in
HCC (Figure 4B).
Immunohistochemical analysis in hamster model of CC
Although it is unknown whether antibodies raised to
human proteins recognize hamster proteins, we exam-
ined the protein levels of the identified genes using
immunohistochemical analysis of hamster CC tissues
(Additional file 5). As in humans, the SPP1, EFNB2, and
E2F2 proteins were abnormally overexpressed in the
hamster CC cell cytoplasm. IRX3 was also similarly
expressed in the CC cell nucleus, and PTTG1 was dif-
ferentially expressed in the CC cell cytoplasm. Interest-
ingly, in contrast to human CC cells, PPARg was
preferentially expressed in the hamster CC cell nuclei.
Therefore, the immunoreactivity of identified gene pro-
teins in hamster CC seemed to be substantially consis-
tent with that in human CC.
Gene expression patterns distinguish the SCK cell line
from three CC cell lines
Previously, we established four human CC cell lines and
characterized one with a typical sarcomatoid phenotype of
SCK. We classified the other cell lines according to tumor
cell differentition, as a poorly differentiated JCK, a moder-
ately differentiated Cho-CK, and a well-differentiated
Choi-CK cell line [34]. Two-way unsupervised hierarchical
clustering analysis of quadruplicate samples for each cell
line was conducted, based on the similarity of expression
patterns of all genes (Figure 5). We selected 559 unique
genes whose expression differed from the mean by four-
fold or more with P < 0.005 by t-test. Cell samples were
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Figure 2 Unsupervised hierarchical clustering of 4 biliary epithelial cells and 19 CC tissues. (A) Unsupervised hierarchical clustering
separated the samples into two main groups. We selected 1798 unique genes with two-fold or greater difference from the mean with P < 0.01
by t-test for hierarchical clustering analysis. Specific gene clusters (Cluster 1 through Cluster III) were identified of differentially expressed in CCT
compared to NBE. (B) Supervised hierarchical clustering of four biliary epithelial cells and seven differentiated CC tissues. We selected 420 unique
genes with four-fold or greater difference from the mean and P < 0.01 by t-test for hierarchical clustering analysis. (C) Supervised hierarchical
clustering of 4 biliary epithelial cells and 10 undifferentiated CC tissues. We selected 646 unique genes with the criteria in B for hierarchical
clustering analysis.
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Page 10 of 15separated into two main groups, sarcomatoid (SC) and
ordinary or adenocarcinomatous CC (AC), by the gene
axis. The SC group contained 292 differentially upregu-
lated genes (>four-fold change), and 267 downregulated
genes (<0.25-fold change), compared to the AC group.
The top 25 genes that were differentially expressed in the
sarcomatoid SCK cells compared to the three adenocarci-
nomatous CC lines are in Additional file 6. Clustering data
within groups revealed that the core clusters I and II were
associated with transdifferentiation. Genes in cluster I
appeared to be downregulated in the SCK cells, compared
to ordinary CC cells. In contrast, the genes in cluster II
were upregulated in the SCK cells and downregulated in
the ordinary CC cells. Cluster I contained the GSTT1,
TACSTD, BST2, RAB25,a n dMAL2 genes. Cluster II con-
tained genes associated with tumor progression and
metastasis, including HOXA9, MUC13, and members of
the GAGE and CT-45 families [35-38]. Expression of
methylation-silenced genes, such as LDHB, BNIP3,
UCHL1, and NPTX2 [39-42], was barely detectable in the
AC group, but appeared in this cluster.
Expressions of transdifferentiation-related genes
From 559 genes that were differentially regulated
between SCK cells and the three ordinary CC lines, we
selected six upregulated genes and six downregulated
genes, and examined their mRNA expression using real-
time RT-PCR (Figure 6A), which verified the differential
expression. We examined protein expression by Western
blot analysis of the four CC lines. LDHB, Bnip3, HO-1,
and UCHL1 were overexpressed exclusively in SCK
cells. The expression of VIM and TWIST1 increased
according to tumor dedifferentiation and was highest in
SCK cells (Figure 6B, left). In contrast, LCN2, S100P,
KRT7, KRT19, GPX1, and EFNA1 were preferentially
expressed in Choi-CK, Cho-CK and JCK cells, but mini-
mally expressed in SCK cells (Figure 6B, right). Because
LDHB, BNIP3, and UCHL1 are well-known methylation-
silenced genes in tumors [39-41], and are highly
expressed in SCK cells, this suggested that DNA
demethylation was involved in CC. To confirm this
hypothesis, we treated the AC cells with the demethylat-
ing agent Aza, which dramatically restorated expression
of the silenced UCHL1 gene in these cells (Figure 6C).
In addition, we performed immunohistochemical exami-
nation of protein expression according to tumor dedif-
ferentiation in human CC tissue (Figure 6D). As
expected, HO-1 was exclusively overexpressed in
SC, while TWIST1 was overexpressed in the poorly
differentiated and SC cells. In contrast, LCN2 was exclu-
sively downregulated in SC, while EFNA1 expression
decreased with tumor dedifferentiation. Therefore,
expression of these proteins clearly correlated with
clinicopathological features such as tumor differentiation
and EMT change, in CC tissues.
Discussion
In this study, our experimental design primarily investi-
gated the gene expression profiles of 10 cell lines and 19
CC tissues, and compared these profiles to those from
four cultured NBE cell line using genome-wide Bead-
Chip microarray analysis. Transdifferentiation-related
genes were analyzed by same method. Using unsuper-
vised hierarchical clustering analysis, we found that the
SPP1, EFNB2,a n dE2F genes were commonly upregu-
lated in both cell and tissue samples. IRX3, PTTG1,a n d
PPARg were upregulated in the cell samples, and were
immunohistochemically verified in human and hamster
CC tissues. SPP1 (osteopontin), a secretory adhesive aly-
coprotein, was identified as a highly overexpressed gene
in CC lines and tissues. SPP1 is a ligand of CD44 that
binds to aV-containing integrins and is important in
malignant cell attachment and tumor invasion [43]. It
was a highly overexpressed gene in HCC, and its expres-
sion correlated with earlier recurrence, poorer prognosis,
and metastasis [44]. Consistent with our findings, a
recent oligonucleotide microarray study reported that
SPP1 was the most highly expressed gene in intrahepatic
cholangiocarcinoma [45]. EFNB2 was identified as a pre-
ferentially expressed genes in CC. EFNB2 overexpression
is reported to be significantly correlated with the num-
ber of lymph node metastases and clinical stage in eso-
phageal cancer [46]. Several reports have examined
concomitant expression of the ligand EFNB2 and its
receptor EphB4 in leukemia-lymphoma cell lines [47],
and in endometrial cancer [48]. E2Fs 1-3 are character-
ized as “activator E2Fs” since their binding to promoters
results in increased transcription, while E2Fs 4 and 5
are “repressor E2Fs” s i n c et h e yf o r mc o m p l e x e sw i t h
p130, HDACs, and other factors to block transcription
[49]. During hepatocarcinogenesis in c-myc/TGFalpha
double-transgenic mice, expression of E2F-1 and E2F-2
increases, and putative E2F target genes are induced
[50].
For immunohistochemical verification, the representa-
tive genes were selected from the list of top 25 com-
monly upregulated genes, according to antibody
available for immunohistochemistry. In addition, other
genes were selected from only cell-based microarray
database. The same immunohistochemical staining in
hamster CC tissues induced by Clonorchiasis infestation
was compared with control staining in normal hamster
livers. IRX3 is involved in dorsal-ventral patterning in
spinal cord development and coordination with other
homeobox genes [51]. IRX3 is preferentially expressed
in the examined CC tissues and localized to the nucleus
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Figure 6 Genes and proteins differentially expressed in sarcomatoid CC and adenomatous CC cells.( A )R e a l - t i m eR T - P C Ra n a l y s i so f
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Page 12 of 15of human and hamster malignant biliary epithelial cells,
independent of cell differentiation. A methylated CpG
island was detected in exon 2 of the IRX3 locus, rather
than in the promoter, and is responsible for IRX3 over-
expression in brain tumor cells and tissues [52]. PTTG1,
a critical mitotic checkpoint protein, is a known proto-
oncogene that is highly expressed in HCC [53]. Our
data showed that PTTG1 was preferentially expressed in
the cytoplasm of the human and hamster CC cells.
PPAR-g, a member of the nuclear receptor superfamily,
functions as a ligand-activated transcription factor [54].
It is overexpressed in a variety of cancers, including
HCC and pancreatic cancer [55,56]. Positive immunos-
taining was localized in the cytoplasm and nuclei of
human CC cells. However, positive immunostaining was
exclusively detected in the nuclei of the hamster CC
cells. Our data also immunohistochemically validated
the downregulation of proteins KRT17, UCHL1,
IGFBP7, and SPARC. Our hamster model showed the
similar expression patterns of human CC related genes
and therefore might be a relevant model to study
human CC.
Analysis of genes involved in the transdifferentiation
of CC cells showed two clusters in the gene axis, with
genes that were upregulated (cluster II), and downregu-
lated (cluster I) in the SC group as compared to the AC
group. The mesenchymal antigen VIM and the tran-
scriptional factor TWIST1 were upregulated in JCK and
SCK cells by tumor dedifferentiation. The overexpres-
sion of these proteins is reported to be associated with
the EMT [57,58]. Intriguingly, genes silenced by promo-
ter hypermethylation during CC development were
restored at the point of sarcomatous transdifferentation,
which implied that the demethylation may be involved
in the EMT progression of CC.
In addition to tumor-related genes known to be over-
exprssed in intrahepatic CC, we identified other strongly
and consistently dysregulated genes in CC that are
known to be involved in other human cancers. Our data
support a correlation between the expression of these
genes and CC tumor differentiation, and the gene expres-
sion patterns found in this study are consistent with
those associated with a poor clinical prognosis for this
cancer. gene expression profiling appears to be a useful
diagnostic tool, especially for differentiating CC from
other liver masses, as well as for the subclassification of
intrahepatic CC compared to histopathological findings.
Conclusions
Gene expression profiling appears to be a useful diag-
nostic tool, especially for differentiating CC from other
liver masses, as well as for the subclassification of intra-
hepatic CC compared to histopathological findings. The
most consistently overexpressed genes are candidate
therapeutic targets, and related genes can be used for
predicting survival and outcomes for different therapeu-
tic modalities.
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